Signals and trends of Guillain–Barré syndrome after the introduction of live-attenuated vaccines for influenza in the US and South Korean adverse event reporting systems
- 27 June 2020
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 38 (34), 5464-5473
- https://doi.org/10.1016/j.vaccine.2020.06.038
Abstract
No abstract availableFunding Information
- Government-wide R&D Fund for Infectious Diseases (HG18C0068)
This publication has 35 references indexed in Scilit:
- The Korean Influenza National Immunization Program: History and Present StatusInfection & Chemotherapy, 2017
- A global review of national influenza immunization policies: Analysis of the 2014 WHO/UNICEF Joint Reporting Form on immunizationVaccine, 2016
- Guillain-Barré syndromeThe Lancet, 2016
- Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2012
- Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoringVaccine, 2009
- Economic cost of Guillain-Barré syndrome in the United StatesNeurology, 2008
- Guillain-Barré Syndrome and Preceding Infection with Campylobacter, Influenza and Epstein-Barr Virus in the General Practice Research DatabasePLOS ONE, 2007
- The macroepidemiology of influenza vaccination in 56 countries, 1997–2003Vaccine, 2005
- The Economic Impact of Pandemic Influenza in the United States: Priorities for InterventionEmerging Infectious Diseases, 1999
- GUILLAIN-BARRE SYNDROME FOLLOWING VACCINATION IN THE NATIONAL INFLUENZA IMMUNIZATION PROGRAM, UNITED STATES, 1976–19771American Journal of Epidemiology, 1979